RBP2 and colon adenocarcinoma: RBP2 exhibited significant downregulation across several tumors, including KICH, KIRC, KIRP, LUAD, LUSC, and thyroid carcinoma (THCA), with elevated expression observed in breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), and LIHC (Figure 1B).